Sarah Cannon appoints lung cancer research program director
Click Here to Manage Email Alerts
Melissa Johnson, MD, has been appointed program director of lung cancer research for Sarah Cannon.
Johnson has served as associate director of lung cancer research at Sarah Cannon Research Institute since 2014. In her new role, she will lead the lung cancer clinical trial portfolio across the Sarah Cannon network.
“Since joining Sarah Cannon, Dr. Johnson’s contributions to research have helped transform the treatment options available to patients facing lung cancer,” David Spigel, MD, Sarah Cannon’s chief scientific officer, said in a press release. “As program director of lung cancer research, Dr. Johnson will continue to help advance therapies for our patients today and in the future.”
Johnson will continue to lead Sarah Cannon’s tumor immune effector cellular therapy program. She also will continue her work in early-phase drug development and caring for patients as a partner with Tennessee Oncology.
Read more about
Click Here to Manage Email Alerts